No Detail Found!

Hepatocellular Carcinoma (HCC) in HCV-Related Liver Cirrhosis After Sustained Viral Response (SVR)

Author(s)
Syed Hasnain Abbas Pir Abdul Qadir Shah Jeelani Institute of Medical Sciences,Gambat, Sindh, Pakistan
Azhar Hussain Pir Abdul Qadir Shah Jeelani Institute of Medical Sciences, Gambat, Sindh, Pakistan
Hafiz Fahad Ullah Saeed King Edward Medical University, Mayo Hospital, Lahore, Pakistan
Muhammad Usman King Edward Medical University, Mayo Hospital, Lahore, Pakistan
Madho Mal Liaquat University of Medical & Health Sciences, Jamshoro, Pakistan
Usman Ismail King Edward Medical University, Mayo Hospital, Lahore, Pakistan
Muhammad Umair King Edward Medical University, Mayo Hospital, Lahore, Pakistan
Muhammad Furqan King Edward Medical University, Mayo Hospital, Lahore, Pakistan
Talal Khurshid Bhatti SZABMU & PIMS, Islamabad, Pakistan
Ejaz Shah HSHS Saint John Hospital Internal Medicine, Springfield, USA
Abstract
Objective: Effectiveness of the direct-acting antivirals (DAAs) regarding the achievement of SVR post-treatment and its impact on the future occurrence of hepatocellular carcinoma (HCC) post-treatment of DAAs in Hepatitis C-related liver cirrhosis. Methods: It was a cohort study that was done on 359 Hepatitis C patients who were given Ribavarin-Sofosfubuvir & Daclatasvir. We experienced 41.1% (158) lost follow-up. Only 86/201 (43.2%) completed follow-up. The study population was divided into two groups (SVR achieved vs didn't SVR achieve). Each group was further subdivided into two groups: developed HCC or did not develop HCC post-treatment of DAAs. Results: 86 subjects who had median age of 50.6 ± 10.65 years who completed triple therapy regime and follow-up, were analyzed. The average follow-up period was 45 weeks (24-68 weeks). Out of 86 patients, 81 (94%) achieved SVR12 with triple therapy of Sofosbuvir-Daclasavir plus Ribavirin. Only 2(2.4%) patients out of 81 developed HCC after the achievement of SVR, while 3/5 (60%) of patients developed HCC who did not achieve SVR. The rate of achievement of SVR was quite lower in the group diagnosed with HCC than those who did not develop HCC post-treatment of DAAs (66.6% v 96.8%, p=0.023). HCC occurrence duration was 31-48 weeks after SVR achievement post-treatment of DAAs. Conclusion: SVR achieved by Sofosbuvir-Daclasavir plus Ribavirin plus ribavirin decreases the occurrence of HCC but doesn't eliminate the chances of developing HCC (66.3 %- or 3.3 times lesser risk).
Publication Details
Page(s) 29-34
DOI DOI not available
Published Journal: Journal of Pakistan Society of Internal Medicine, Volume: 4, Issue: 1, Year: 2023

Request the full text from PASTIC

Keywords
Liver Cirrhosis, Hepatocellular Carcinoma (HCC), Sustained viral response
0

Citations

0

Downloads

62

Views